You are here

BCRF Grantee Since


Donor Recognition

The Play for P.I.N.K. Award

Area(s) of Focus

John M.S. Bartlett, PhD

Director, Transformative Pathology Platform and the Ontario Tumor Bank
Ontario Institute for Cancer Research
Honorary Professor, The University of Edinburgh
Toronto, Ontario

Current Research

Male Breast Cancer (BC) is a rare disease accounting for less than 1 percent of all BC. Knowledge about male BC is scarce, and treatment and management is based on female BC. To better characterize this disease and ultimately develop specific treatments and improve outcomes for men with BC, the Male Breast Cancer International Program was created. Dr. Bartlett is part of a team of BCRF grantees participating in this worldwide effort coordinated by the European Organization for the Research and Treatment of Cancer (EORTC), with the help of the Translational Breast Cancer Research Consortium (TBCRC), and run under the network of the Breast International Group (BIG) and the North American Breast Cancer Groups (NABCG). This Program has three parts. Part One is a retrospective joint analysis of clinical data and tumor samples from 1822 male breast cancer patients treated in the last 20 years in 23 centers from 9 countries, the largest series of male breast cancer ever studied. The first results of the retrospective study were presented at the San Antonio Breast Cancer Symposium in 2014. Part Two of the study is focused on creating a registry of all male breast cancer patients treated within the EORTC/TBCRC/BIG/NABCG global network and includes collection of biological material that can be used for future studies.  This part is ongoing with over 100 patients included. The researchers are currently conducting in-depth biological characterization of the samples. Part Three is a prospective clinical trial, expected to open in late 2015, that will evaluate a new drug to treat male breast cancer. This important work will lead to the development of better treatment strategies for male breast cancer. 


Professor John Bartlett is Professor of Molecular Pathology at Edinburgh University, Fellow of the Royal College of Pathologists and the Group Leader of the Endocrine Cancer Group at the University of Edinburgh Cancer Research Centre at the Western General Hospital. Dr Bartlett graduated in 1982 with a B.Sc (hons) in Biochemistry and subsequently a PhD in reproductive physiology in 1985. His interest in cancer research and molecular biology started in 1990 and he joined the University of Edinburgh in March 2006. Over the past 10 years he has developed research into the molecular biology of breast cancer during which time he has developed a significant expertise in translational science in breast cancer and the pathobiology of type I receptor tyrosine kinases. He is the author of over 125 papers. Dr John Bartlett is also involved in the TRANSBIG research network and in scientific working groups as part of the Breast International Group (BIG) network.